



INPP4B促进结直肠癌转移及其作用机制的初步探索*

赖萌¹, 毛志刚², 唐邓¹, 兰思琪¹, 晏蕊婷¹, 向琦¹, 赵暹暹¹, 苏宓¹, 王玉芳^{1△}

1. 四川大学华西基础医学与法医学院(成都 610041); 2. 四川大学华西医院 实验医学科(成都 610041)

【摘要】目的 明确肌醇多磷酸4-磷酸酶II型(inositol polyphosphate-4-phosphatase type II B, INPP4B)在结直肠癌(colorectal cancer, CRC)中的表达及临床意义,明确CRC细胞中INPP4B与基质金属蛋白酶7(matrix metalloproteinase 7, MMP7)的关系,并初步探究INPP4B对CRC细胞的增殖、迁移的影响及机制。**方法** 使用TIMER2.0和GEPIA2数据库分析INPP4B在癌(瘤)和癌旁(瘤旁)组织中的表达差异和对CRC预后的影响;通过免疫组化检测临床手术切除的102例CRC肿瘤中INPP4B的表达,并分析INPP4B与临床病理指标的相关性;在过表达/敲减INPP4B的CRC细胞中,实时荧光定量PCR检测INPP4B和MMP7的基因表达,Western blot检测INPP4B蛋白表达,利用CellTiter 96® AQueous One检测细胞增殖,划痕实验、实时无标记动态细胞分析技术(RTCA)检测细胞迁移和侵袭;结合LinkedOmics数据库分析与INPP4B功能相关信号通路,并在细胞水平验证潜在的关键分子。**结果** 数据库分析结果显示,与正常组织相比(结肠癌: 1.91, 直肠癌: 1.89),在CRC中INPP4B表达升高(结肠癌: 2.30, 直肠癌: 2.33)。免疫组化检测临床肿瘤组织和肿瘤旁组织也证实INPP4B在CRC中表达增高($P < 0.001$)。Cox回归模型分析显示INPP4B[风险比(HR)=1.457, 95%置信区间(CI): 1.003 ~ 2.115]影响CRC预后, Kaplan-Meier曲线显示INPP4B高表达患者生存期短($P < 0.05$); χ^2 检验分析INPP4B表达与临床病理指标,发现INPP4B的高表达与淋巴结转移($\chi^2 = 3.997, P = 0.046$)和神经浸润($\chi^2 = 8.511, P = 0.004$)相关。体外实验中,与对照组细胞相比,过表达INPP4B的CRC细胞增殖和迁移能力增加($P < 0.05$)。通过LinkedOmics数据库分析显示INPP4B与细胞外基质重塑和细胞转移相关; Pearson相关性分析显示MMP7与INPP4B正相关($r = 0.3782, P < 0.001$);体外过表达或敲减INPP4B后MMP7表达水平也随之升高和下降。**结论** INPP4B在结直肠肿瘤组织中呈高表达并与淋巴结转移、神经浸润、患者预后相关。MMP7可能介导了INPP4B促进CRC细胞迁移和侵袭的作用。

【关键词】 肌醇多磷酸4-磷酸酶II型 结直肠癌 基质金属蛋白酶7

Preliminary Study of the Role of INPP4B in Promoting Colorectal Cancer Metastasis and the Mechanisms Involved

LAI Meng¹, MAO Zhigang², TANG Deng¹, LAN Siqi¹, YAN Ruiting¹, XIANG Qi¹, ZHAO Xianxian¹, SU Mi¹, WANG Yufang^{1△}. 1. West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu 610041, China; 2. Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

△ Corresponding author, E-mail: wangyufang@scu.edu.cn

【Abstract】 Objective To investigate the expression of inositol polyphosphate 4-phosphatase type II B (INPP4B) in colorectal cancer (CRC) and the relevant clinical significance, to determine the relationship between INPP4B and matrix metalloproteinase 7 (MMP7) in CRC cells, and to make preliminary exploration of the effects of INPP4B on the proliferation and migration of CRC cells and mechanisms involved. **Methods** The TIMER2.0 and GEPIA2 databases were used to analyze the differences in INPP4B expression between cancer and para-cancerous tissues and the effects of such differences on the prognosis of CRC. The expression of INPP4B in 102 surgically resected CRC tumors was determined by immunohistochemistry (IHC), and the correlation between INPP4B and clinical pathological indicators was analyzed. In CRC cells with overexpressed/knocked-down INPP4B, the expression of INPP4B and MMP7 were examined by real time fluorogenic quantitative PCR, the protein expression of INPP4B was assessed by Western blot, cell proliferation was determined using the CellTiter 96® AQueous One assay, and cell migration and invasion were assessed using wound healing assay and real-time label-free dynamic cell analysis (RTCA). The LinkedOmics database was used to analyze signaling pathways related to INPP4B function, and the role of potential key molecules was validated at the cellular level. **Results** Analysis with the TIMER2.0 database and GEPIA2 database showed elevated INPP4B expression (colon adenocarcinoma [COAD]: 2.30, rectal adenocarcinoma [READ]: 2.33) in CRC compared to normal tissue (COAD: 1.91, READ: 1.89). IHC testing confirmed that INPP4B was upregulated in clinical CRC tissues and paracancerous tissues ($P < 0.001$). Cox regression model analysis showed that INPP4B (hazards ratio [HR]=1.457, 95% confidence interval [CI]: 1.003-2.115) affected the prognosis of CRC, and the Kaplan-Meier curve showed that patients with high INPP4B expression had shorter overall survival ($P < 0.05$). χ^2 test was performed to analyze the relationship between INPP4B

* 国家自然科学基金(No. 82173104, No. 81871233)资助

△ 通信作者, E-mail: wangyufang@scu.edu.cn

出版日期: 2024-09-20

expression and clinicopathological indexes, and it was found that high expression of INPP4B was correlated with lymph node metastasis ($\chi^2=3.997$, $P=0.046$) and neural invasion ($\chi^2=8.511$, $P=0.004$). In *in vitro* experiments, CRC cells overexpressing *INPP4B* showed a significantly increased cell proliferation and migration compared to the cells in the control group ($P<0.05$). Analysis using the LinkedOmics database showed that *INPP4B* was correlated with extracellular matrix remodeling and cell migration. Pearson's correlation analysis showed that *MMP7* was positively correlated with *INPP4B* ($r=0.3782$, $P<0.001$). *INPP4B* overexpression or knockdown *in vitro* also led to the upregulation or the downregulation of *MMP7* expression in CRC cells. **Conclusion** *INPP4B* is highly expressed in CRC tissues and significantly correlated with lymph node metastasis, neural invasion, and patient prognosis. *MMP7* may mediate the role of *INPP4B* in promoting CRC cell migration and invasion.

【Key words】 INPP4B Colorectal cancer MMP7

结直肠癌(colorectal cancer, CRC)是全球肿瘤相关死亡的第二大原因^[1]。在我国,2022年CRC新发病例59.2万,死亡病例30.9万,发病率居所有恶性肿瘤第2位,死亡率居第4位^[2],CRC患者5年生存率为56.9%,远低于欧美国家^[3],而转移性CRC的5年生存率不足20%^[4]。因此,探明CRC的发生发展机制有助于改善临床治疗效果,改善CRC患者预后。

肌醇多磷酸4-磷酸酶 II 型(inositol polyphosphate 4-phosphatase type II B, INPP4B)是磷脂酰肌醇 3-激酶(phosphatidylinositol 3-kinase, PI3K)信号通路的关键激酶,募集并激活Akt的磷脂酰肌醇3, 4-二磷酸[PI(3,4)P₂]去磷酸化,抑制Akt的活化,进而抑制Akt下游信号通路,抑制细胞的增殖、代谢、迁移等^[5]。因此INPP4B通常被认为是通过负调节Akt活化来实现肿瘤抑制作用。但是有关INPP4B在CRC中的研究结果并不一致,有研究者表明INPP4B在肿瘤中表达下降,也有研究者报道INPP4B可以促进CRC的发生发展^[6-7]。关于INPP4B对CRC细胞增殖的作用已有较多探讨,对CRC转移的作用尚缺乏研究。因此,需要进一步明确INPP4B在CRC中的作用以及探索INPP4B对CRC转移的影响。

基质金属蛋白酶7(matrix metalloproteinase 7, MMP7),又称为基质溶血素,可通过分解多种细胞外基质成分,促进癌症的转移和血管生成等^[8]。MMP7被发现CRC中呈高表达^[9-10],尚没有研究表明INPP4B与MMP7的相关性及在CRC中的作用。

本研究拟通过生物信息学分析、临床样本的检测以及细胞水平的验证,明确INPP4B对CRC转移的影响,并明确CRC细胞中INPP4B与MMP7表达的相关性,为探究临床INPP4B高表达CRC患者发病机制提供新的思路。

1 资料与方法

1.1 公共数据集的分析

利用TIMER2.0数据库^[11-13]分析INPP4B在肿瘤中的表

达情况,采用Cox模型分析INPP4B、年龄、性别、种族、肿瘤纯度、肿瘤分期对结肠癌(colon adenocarcinoma, COAD)患者预后的影响,并做Kaplan-Meier曲线。用GEPIA2数据库^[14](<http://gepia2.cancer-pku.cn/#general>)分析TCGA和GTEx数据库中癌和癌旁中INPP4B的表达情况。用LinkedOmics在线数据库^[15](<http://www.linkedomics.org/admin.php>),选择TCGA-COAD/直肠癌(rectum adenocarcinoma, READ)数据队列,对组织分型为COAD的RNaseq数据集进行INPP4B的Pearson相关性分析。使用过表达富集分析法(ORA)富集INPP4B正相关基因的GO_BP。

1.2 临床CRC样本采集

收集2015年1月-2021年12月四川大学华西医院手术切除、临床及病理资料完整的102例样本,以及26对癌(瘤)与癌旁(瘤旁)CRC样本。所有患者术前均未接受任何放疗及靶向治疗,所有标本均经两位病理医师复阅、确诊,并按WHO消化系统肿瘤分类标准确定病理分级及分期。本研究经四川大学华西医学中心医学伦理委员会批准(批准号KS2021548),样本收集已获得患者知情同意。

1.3 免疫组化分析

组织样本经固定、包埋、脱蜡、水化,过氧化氢溶液消除内源性过氧化物酶,后使用TRIS-EDTA(pH=9.0)对组织进行抗原修复。一抗INPP4B(CST, 14543)稀释浓度为1:600,二抗为生物素化二抗,使用DAB显色,最后采用苏木素复染。显微镜下判读结果,每张切片随机选择5个高倍视野($\times 400$)进行观察,每个视野随机计数100个细胞,按照着色程度评分:未着色为0分,浅黄色为1分,棕黄色为2分,深褐色为3分。单独评分两次,对两次评分求均值(IHC SCORE=1.215),将102例具有完整病理资料的样本按此均值分为INPP4B高表达组38例、INPP4B低表达组64例。

1.4 INPP4B过表达/敲减细胞系的构建

PCR扩增(TaKaRa TaqTM)人INPP4B(*hINPP4B*)

(NM_001101669)的cDNA,采用双核酸限制性内切酶 *Bam*H I (NEB, R3136)和*Eco*R I (NEB, R0101)、将cDNA插入过表达载体Lenti-EF1a-MCS-Flag.His-CMV-GFP-Puro(Addgene),构成Lenti-EF1a-*hINPP4B*-Flag.His-CMV-GFP-Puro质粒。使用BLOCK-iT™ RNAi Designer (<https://rnaidesigner.thermofisher.com/rnaexpress/>)设计shRNA序列并合成(擎科生物),退火后形成双链DNA。采用双核酸限制性内切酶*Bam*H I 和*Eco*R I、敲减载体Lenti-U6-shNT-SV40-GFP-Puro(Addgene),插入合成的双链shRNA,连接后构建Lenti-U6-sh*INPP4B*-SV40-GFP-Puro。用DH5α大肠杆菌(*tolobio*)转化后摇菌、提质粒。将构建好的质粒及其阴性对照与慢病毒包装辅助质粒psPAX2和Pmd2.G与转染试剂PEI(MCE)混合后转染HEK293T细胞(Harvard Medical School)。收集24 h、48 h的转染细胞上清液,过滤后加入Polybrene(10 μg/mL)(MCE),将病毒转染进HCT8、HKe3细胞(山西省肿瘤医院),转染完成后用Puromycin(6 μg/mL)(APEX BIO)进行筛选。获得*INPP4B*过表达细胞株HCT8^{INPP4B-OE}和*INPP4B*敲减细胞株HKe3^{INPP4B-KO}及对应的空质粒对照细胞株HCT8^{CTL-OE}、HKe3^{CTL-KO}。

1.5 Western blot

用RIPA蛋白裂解液(Beyotime)裂解细胞,提取总蛋白,SDS-PAGE凝胶电泳。蛋白定量采用Bradford法。检测抗体为*INPP4B*(CST, 4039), β -actin(Sigma-Aldrich, ABT1485)用作内参,二抗Anti rabbit IgG(CST, 7074), Anti Mouse IgG(CST, 7076), ECL 曝光试剂盒(Cytiva, RPN2235), ImageQuant LAS 4000化学发光成像分析仪(GE healthcare)。

1.6 实时荧光定量PCR

用TRIZOL(Ambion)裂解细胞沉淀,加入氯仿后离心,收集上层水相到无RNase管中,加入异丙醇离心沉淀RNA。乙醇清洗,无酶水溶解后nanodrop(Thermo)测量RNA浓度。使用逆转录试剂盒(Promega, A2971)将RNA逆转录为cDNA, qPCR试剂盒(Promega)检测目的基因Ct值。引物由擎科生物公司合成,序列见表1,反应程序如下:95 °C 2 min, 1个循环;95 °C 15 s, 60 °C 30 s, 40个循环。以*GAPDH*作为内参,使用 $2^{-\Delta\Delta Ct}$ 计算基因相对表达量,实验重复3次。

1.7 细胞划痕实验

将对数生长期的HCT8、HKe3细胞胰酶消化后离心重悬,计数后接种于6孔板中。敷箱过夜,第二日垂直地在板孔中央划线,PBS清洗3次,洗去划落的细胞,加入无血清培养基2 mL,放入培养箱。分别于0、12、24 h选取固

表 1 引物序列

Table 1 Primer sequences

Gene name	Primer sequences (5' to 3')	Product length/bp
<i>INPP4B</i>	F: CTGATGCTGACGCTAAGAAGAG	108
	R: TAGGAAGCCTGGGTCATACA	
<i>MMP7</i>	F: GCTGACATCATGATTGGCTTTGCG	238
	R: CTGCATTAGGATCAGAGGAATGTCCC	
<i>GAPDH</i>	F: GGTGTGAACCATGAGAAGTATGA	123
	R: GAGTCCTTCCACGATACCAAAG	

INPP4B: inositol polyphosphate 4-phosphatase type II B; *MMP7*: matrix metalloproteinase 7; *GAPDH*: glyceraldehyde-3-phosphate dehydrogenase.

定视野进行拍照并进行分析。

1.8 实时无标记动态细胞分析技术 (RTCA)

将165 μL含有10%FBS的DMEM细胞培养基加入到CIM-plate的下室中,在预先铺设好基质胶的CIM-plate上室孔中加入100 μL混合均匀的无血清各分组细胞悬液,细胞密度为 $4 \times 10^4 \text{ mL}^{-1}$,加好后的CIM板置于超净台中室温放置30 min后放到培养箱中的RTCA仪器(Agilent, xCELLigence RTCA DP)上进行连续阻抗记录。通过每15 min连续阻抗记录测量24 h的CELL INDEX值反映细胞侵袭迁移能力。CELL INDEX值越高,细胞侵袭、迁移能力越高。

1.9 细胞增殖实验

胰酶消化对数生长期的细胞,计数后重悬,以 4×10^3 个/孔接种于96孔板,分别在接种细胞后的1、3、5、7 d每孔加入15 μL CellTiter 96® Aqueous One试剂(Promega)和100 μL培养基,敷箱孵育2 h,酶标仪检测490 nm处的吸光度值。吸光度值正比于细胞增殖能力。

1.10 统计学方法

采用GraphPad Prism 8软件(GraphPad Software, San Diego, CA, USA),多组间比较采用方差分析(ANOVA),组间两两比较使用*t*检验。采用IBM SPSS Statistics V21.0中 χ^2 检验分析*INPP4B*高低表达两组间临床病理指标。使用TIMER2.0数据库的患者资料,以Cox比例风险模型探究CRC的危险因素,利用Kaplan-Meier法分析*INPP4B*与CRC患者终点事件的关系。使用LinkedOmics中的Pearson相关性分析探究*INPP4B*与*MMP7*的相关性。 $P < 0.05$ 为差异有统计学意义。

2 结果

2.1 公共数据集初步筛选

2.1.1 *INPP4B*在CRC肿瘤组织高表达

使用GEPiA2数据库结合TCGA和GTEx的数据分析*INPP4B*表达情况,结果显示*INPP4B*在CRC中的表达高于正常样本(图1A)。




图 1 INPP4B在CRC组织中的表达情况

Fig 1 Expression of INPP4B in CRC cancer tissue samples

A, The expression of *INPP4B* in COAD (275 in tumor group and 349 in normal controls) and READ (92 in tumor group and 318 in normal controls) was analyzed using the GEPIA2 database combined with TCGA and GTEx data; B, the expression of *INPP4B* was determined by IHC in 26 pairs of colorectal tumor tissue and matching normal tissue samples (***P*<0.001). COAD: colon adenocarcinoma; READ: rectal adenocarcinoma; TPM: transcripts per kilobase million; HT: human tumor; HN: human normal.

本研究在临床收集到26例成对结直肠肿瘤组织与相应正常组织样本, IHC检测INPP4B表达情况。结果发现INPP4B在结直肠肿瘤中的表达情况明显高于肿瘤旁正常组织(图1B)。

2.1.2 *INPP4B*与CRC的生存预后相关

Cox模型显示(表2), 在TIMER2.0数据库完成随访的258例COAD患者中(包括64例死亡), *INPP4B*的表达[风险比(hazard ratio, HR)=1.457, 95%可信区间(confidence interval, CI): 1.003 ~ 2.115], 年龄(HR=1.027, 95%CI: 1.004 ~ 1.050)以及分期(stage 4)(HR=7.030, 95%CI: 表2 Cox模型评估TIMER2.0数据库中*INPP4B*对COAD生存的影响(n=258)

Table 2 Using the Cox model to evaluate the effect of *INPP4B* on the overall survival of COAD (n=258)

Variable	HR	95% CI	P
<i>INPP4B</i> expression			
No	1	Ref	
Yes	1.457	1.003-2.115	0.048
Purity	0.879	0.271-2.855	0.830
Age	1.027	1.004-1.050	0.023
Sex			
Female	1	Ref	
Male	1.279	0.755-2.167	0.360
Race			
Others	1	Ref	
Black	0.611	0.124-3.019	0.545
White	0.578	0.128-2.611	0.476
Stage			
Stage 1	1	Ref	
Stage 2	1.317	0.437-3.966	0.625
Stage 3	2.192	0.746-6.440	0.154
Stage 4	7.030	2.366-20.894	<0.001

HR: hazard ratio; CI: confidence interval.

2.366 ~ 20.894)与患者生存预后有关(*P*<0.05)。

根据肠上皮*INPP4B*表达水平的中位数将患者分为两组, 比较高表达组和低表达组病例的生存期, 结果提示高表达*INPP4B*的COAD患者生存较差(图2)。




图 2 TIMER2.0数据库中不同*INPP4B*表达水平COAD患者的生存预后 Fig 2 Prognosis for the survival of COAD patients with different expression levels of *INPP4B* in the intestinal epithelium n=129 per group.

2.2 临床验证INPP4B与临床病理指标的关系

根据INPP4B免疫组化评分均值, 将102个临床样本分为INPP4B HIGH组(n=38)和LOW组(n=64), 比较两组间各项临床病理指标的差异。结果发现INPP4B与肿瘤淋巴结转移($\chi^2=3.997, P=0.046$)、神经浸润($\chi^2=8.511, P=0.004$)有关, INPP4B高表达的样本肿瘤淋巴结转移和神经浸润都明显增多(表3)。分析结果并未发现INPP4B与性别、年龄、侵袭程度、分化程度以及肿瘤发生部位有关(*P*>0.05)。

2.3 体外细胞验证INPP4B高表达对CRC细胞增殖、迁移和侵袭的促进

2.3.1 过表达和敲低细胞株的验证

与空质粒转染细胞HCT8^{CTL-OE}相比, 过表达INPP4B的

表 3 102例临床CRC组织中INPP4B表达与临床病理指标的关系
Table 3 The relationship between INPP4B expression and clinical pathological indicators in 102 clinical tissue samples of CRC

Pathological feature	Total	INPP4B expression/case (%)		χ^2	P
		High	Low		
Sex				1.213	0.268
Female	60	25 (41.67)	35 (58.33)		
Male	42	13 (30.95)	29 (69.05)		
Age				1.063	0.301
≤60 yr.	47	15 (31.91)	32 (68.09)		
>60 yr.	55	23 (41.82)	32 (58.18)		
Tumor differentiation				2.982	0.225
Low	27	13 (48.15)	14 (51.85)		
Middle	49	19 (38.78)	30 (61.22)		
High	21	5 (23.81)	16 (76.19)		
Tumor invasion				0.601	0.435
T1-T2	28	9 (32.14)	19 (67.86)		
T3-T4	69	28 (40.58)	41 (59.42)		
Lymph node metastasis				3.997	0.046
+	39	19 (48.72)	20 (51.28)		
-	62	18 (29.03)	44 (70.97)		
Neural invasion				8.511	0.004
+	18	12 (66.67)	6 (33.33)		
-	83	25 (30.12)	58 (69.88)		
Anatomic subdivision of the neoplasm				0.210	0.647
Colon	54	19 (35.19)	35 (64.81)		
Rectum	48	19 (39.58)	29 (60.62)		

细胞HCT8^{INPP4B-OE}的INPP4B在基因和蛋白水平表达均升高(图3A)。敲低INPP4B表达的HKE3^{INPP4B-KO}细胞与对照细胞HKE3^{CTL-KO}相比, INPP4B表达水平降低(图3A)。

2.3.2 细胞增殖

通过CellTiter-Glo®发光法检测细胞增殖活力, 观察不同INPP4B表达水平对CRC细胞增殖的影响。结果显示, 过表达INPP4B细胞HCT8^{INPP4B-OE}增殖相比于对照组HCT8^{CTL-OE}明显增高, 而敲低INPP4B表达细胞HKE3^{INPP4B-KO}增殖能力显著受到抑制(图3B)。

2.3.3 细胞迁移和侵袭

划痕实验结果显示(图4A), INPP4B过表达细胞HCT8^{INPP4B-OE}相比于对照组HCT8^{CTL-OE}迁移距离增加, 与之一致的是敲低INPP4B表达细胞HKE3^{INPP4B-KO}相比于对




图 3 INPP4B过表达促进CRC细胞增殖

Fig 3 INPP4B overexpression promotes the proliferation of CRC cells

A, Western blot (left) and RT-PCR (n=3 per group, right) were performed to verify INPP4B expression in transfected cells; B, Cell Titer-Glo® was used to detect the effect of different levels of INPP4B expression on cell proliferation (n=8 per group). * P<0.05, ** P<0.01, *** P<0.001.




图 4 INPP4B过表达促进CRC细胞迁移和侵袭

Fig 4 The overexpression of INPP4B promotes the migration and invasion of CRC cells

A, Wound healing assay was conducted to measure the migration of INPP4B overexpression (n=8 per group) and knockdown (n=10 per group) cell lines; B, RTCA assay was conducted to determine the invasion of INPP4B overexpressing and knockdown cell lines (n=3 per group). # Control (serum-free). * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001.

照组HKE3^{CTL-KO}迁移距离下降。

RTCA检测结果显示(图4B), HCT8^{INPP4B-OE}细胞相比

于对照组HCT8^{CTL-OE}的侵袭迁移能力增强, HKe3^{INPP4B-KO}细胞相比于对照组HKe3^{CTL-KO}的侵袭迁移能力下降。

2.4 INPP4B促进CRC细胞迁移与细胞外基质重塑有关

为进一步研究INPP4B促进细胞迁移的机制, 本研究利用LinkedOmics在线数据进行基因功能分析, 结果显示与INPP4B正相关的基因富集的前3个通路分别是细胞外

基质组成和结构、细胞迁移的正向调控, 提示INPP4B调控CRC转移与重塑细胞外基质高度相关(附图1)。Pearson相关分析的基因热图显示了前50个与INPP4B正相关基因(附图2), 在前10个正相关基因中, MMP7与INPP4B表达水平正相关($r=0.3782$, $P<0.01$) (图5A)。所有附图请见网络资源附件。




图5 CRC的INPP4B表达与MMP7正相关

Fig 5 The expression of INPP4B is positively correlated with MMP7 in CRC

A, Pearson's correlation analysis was performed to analyze the correlation between INPP4B and MMP7; B, qPCR was performed to measure the expression of MMP7 after overexpression ($n=3$ per group) or knockdown ($n=4$ per group) of INPP4B in CRC cells. * $P<0.05$, *** $P<0.001$.

本研究进一步通过qPCR检测INPP4B过表达或敲减细胞中MMP7的表达, 结果如图5B所示。与对照相比, 过表达INPP4B促进了MMP7的表达, 而INPP4B表达水平的下调抑制了MMP7的表达。

3 讨论

在结肠癌发生发展过程中, PI3K通路的激活具有重要意义^[16]。CRC患者常见的遗传和表观遗传异常, 例如EGFR的耐药, KRAS基因突变, BRAF以及PTEN的缺失, 都与PI3K信号的激活高度相关^[17-18]。PI3K信号的激活受到肌醇多磷酸酶的负调节。其中INPP4B这种脂质磷酸酶催化PI(3,4)P₂的4位点去磷酸化降解为PI(3)P, 从而终止PI3K信号。

虽然具有类似功能的PI3K信号的负性调节分子PTEN是一个被公认的抑癌基因, 但有关INPP4B在不同肿瘤中功能的研究结果却截然相反。在三阴性乳腺癌和基底样乳腺癌中INPP4B杂合性缺失的现象频发, 通过延缓EGFR的降解使得Akt信号通路的作用时间延长和直接促使Akt磷酸化增加来促进癌症的发生^[19-20]。INPP4B的缺失可使良性甲状腺瘤转变为致死性和转移性滤泡样甲状腺瘤^[21]。INPP4B蛋白在前列腺癌组织中表达下调^[22], 并且通过抑制PKC信号和Akt活性抑制前列腺癌的侵袭^[23-24]。但INPP4B在不同组织来源的肿瘤中并不都表现为一个抑癌基因。在急性髓系白血病(acute myelogenous leukemia, AML)中促进细胞的增殖^[25]同时还介导了

AML的耐药机制^[26]。

尽管INPP4B对肿瘤增殖和转移的影响已在多种癌症中进行了研究, 但INPP4B在CRC中的功能尚未明确, 目前的研究多聚焦于对CRC细胞增殖的研究。GUO等^[6]在细胞水平上研究发现INPP4B活化结肠癌细胞中PI3K和SGK3信号, 提示INPP4B作为癌基因促进肠上皮的异常增殖^[27]。但也有研究报道INPP4B在原发性和转移性CRC组织中的表达相比与正常肠黏膜的表达降低^[7]。在一项CRC干细胞研究中, INPP4B促进了高度转移性CRC干细胞样细胞(CR-CSLCs)的致瘤性^[28], 提示了INPP4B和转移的关系, 却缺乏进一步的实验验证。

为明确INPP4B在CRC中的作用, 本研究利用多个在线数据库进行生物信息学分析INPP4B在肿瘤和正常组织中的表达与CRC患者预后等关系, 从基因表达层面系统挖掘INPP4B与CRC中进展相关的候选基因集, 并基于临床组织和体外细胞培养水平进行验证。无论从生物信息学、临床样本还是细胞水平实验都发现INPP4B促进了CRC的转移。通过TCGA RNA-seq数据集探索CRC与INPP4B表达水平相关基因, 以及GO富集INPP4B正相关的基因所在通路, 本研究发现INPP4B与细胞外基质组成和结构的高度相关, 在这些通路中MMP7分子被富集, 同时又与INPP4B的表达具有明显的正相关。

MMP7是基质金属蛋白酶家族的一员, 参与前列腺癌^[29]、乳腺癌^[30]等肿瘤的转移。在CRC中发挥着重要的作用, 与细胞增殖、迁移和侵袭, 以及血管形成相关^[8]。

研究表明MMP7因促进CRC的转移^[31],是CRC上皮间质转化的标志物^[32],被视为CRC的潜在具有预后价值的标志分子^[33]。MMP7还与神经浸润相关^[34],这与本研究结果一致。除了参与肿瘤的转移,MMP7在CRC的结肠腺瘤患者血清和组织中升高^[35],可导致CRC的发生,可能是腺瘤-癌序列中的主要事件^[35-36]。MMP7还可激活其他的MMPs,例如MMP1、MMP2、MMP8、MMP9^[37-38],进而参与肿瘤转移、生长等过程。因此,MMP7在CRC发生发展中有重要作用。

然而,MMP7在CRC中的调控机制目前仍不明确。研究表明,PI3K/Akt通路与MMP7表达密切相关。CRC中,PI3K/Akt通路的抑制剂以及Akt的沉默都影响了癌细胞中MMP7的表达,从而影响肿瘤的转移^[39-40]。两者之间的关系也在胃癌^[41]、非小细胞肺癌^[42]和卡希波肉瘤^[43]中得到验证。INPP4B作为PI3K/Akt通路的关键调节因子,很有可能参与了MMP7的调节。本研究在体外细胞水平也证实INPP4B可正向调控MMP7的表达,需要进一步研究明确INPP4B调控MMP7的机制。

综上,本研究明确了INPP4B在CRC中高表达与肿瘤转移、患者预后相关。INPP4B高表达重塑细胞外基质,促进了CRC细胞的转移。

* * *

作者贡献声明 赖萌负责论文构思、数据审编、正式分析、初稿写作和审读与编辑写作,毛志刚负责提供资源和监督指导,唐邓和兰思琪负责调查研究和研究方法,晏蕊婷、向琦和赵暹负责调查研究和验证,苏宓和王玉芳负责论文构思、数据审编、经费获取、初稿写作和审读与编辑写作。所有作者已经同意将文章提交给本刊,且对将要发表的版本进行最终定稿,并同意对工作的所有方面负责。

Author Contribution LAI Meng is responsible for conceptualization, data curation, formal analysis, writing--original draft, and writing--review and editing. MAO Zhigang is responsible for resources and supervision. TANG Deng and LAN Siqi are responsible for investigation and methodology. YAN Ruiting, XIANG Qi, and ZHAO Xianxian are responsible for investigation and validation. SU Mi and WANG Yufang are responsible for conceptualization, data curation, funding acquisition, writing--original draft, and writing--review and editing. All authors consented to the submission of the article to the Journal. All authors approved the final version to be published and agreed to take responsibility for all aspects of the work.

利益冲突 本文作者王玉芳是本刊编委会编委。该在编辑评审过程中所有流程严格按照期刊政策进行,且未经其本人经手处理。除此之外,所有作者声明不存在利益冲突。

Declaration of Conflicting Interests WANG Yufang is a member of the Editorial Board of the journal. All processes involved in the editing and reviewing of this article were carried out in strict compliance with the journal's policies and there was no inappropriate personal involvement by

the author. Other than this, all authors declare no competing interests.

参 考 文 献

- [1] SUNG H, FERLAY J, SIEGEL R L, *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 2021, 71(3): 209-249. doi: 10.3322/caac.21660.
- [2] ZHENG R, ZHANG S, ZENG H, *et al.* Cancer incidence and mortality in China, 2016. *J Natl Cancer Cent*, 2022, 2(1): 1-9. doi: 10.1016/j.jncc.2022.02.002.
- [3] LI N, LU B, LUO C, *et al.* Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America. *Cancer Lett*, 2021, 522: 255-268. doi: 10.1016/j.canlet.2021.09.034.
- [4] BILLER L H, SCHRAG D. Diagnosis and treatment of metastatic colorectal cancer: a review. *JAMA*, 2021, 325(7): 669-685. doi: 10.1001/jama.2021.0106.
- [5] HAMILA S A, OOMS L M, RODGERS S J, *et al.* The INPP4B paradox: like PTEN, but different. *Adv Biol Regul*, 2021, 82: 100817. doi: 10.1016/j.jbior.2021.100817.
- [6] GUO S T, CHI M N, YANG R H, *et al.* INPP4B is an oncogenic regulator in human colon cancer. *Oncogene*, 2016, 35(23): 3049-3061. doi: 10.1038/onc.2015.361.
- [7] SUNG J Y, NA K, KIM H S. Down-regulation of inositol polyphosphate 4-phosphatase type II expression in colorectal carcinoma. *Anticancer Res*, 2017, 37(10): 5525-5531. doi: 10.21873/anticancer.11984.
- [8] HE L, KANG Q, CHAN K I, *et al.* The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer. *Front Immunol*, 2022, 13: 1093990. doi: 10.3389/fimmu.2022.1093990.
- [9] SHATTUCK-BRANDT R L, LAMPS L W, HEPPNER GOSS K J, *et al.* Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. *Mol Carcinog*, 1999, 24(3): 177-187.
- [10] MORI M, BARNARD G F, MIMORI K, *et al.* Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. *Cancer*, 1995, 75(6 Suppl): 1516-1519. doi: 10.1002/1097-0142(19950315)75:6+<1516::aid-cnrcr2820751522>3.0.co;2-7.
- [11] LI T, FAN J, WANG B, *et al.* TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Res*, 2017, 77(21): e108-e110. doi: 10.1158/0008-5472.CAN-17-0307.
- [12] LI T, FU J, ZENG Z, *et al.* TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Res*, 2020, 48(W1): W509-W514. doi: 10.1093/nar/gkaa407.
- [13] LI B, SEVERSON E, PIGNON J C, *et al.* Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. *Gen Biol*, 2016, 17(1): 174. doi: 10.1186/s13059-016-1028-7.
- [14] TANG Z, KANG B, LI C, *et al.* GEPIA2: an enhanced web server for

- large-scale expression profiling and interactive analysis. *Nucleic Acids Res*, 2019, 47(W1): W556–W560. doi: [10.1093/nar/gkz430](https://doi.org/10.1093/nar/gkz430).
- [15] VASAIKAR S V, STRAUB P, WANG J, *et al*. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. *Nucleic Acids Res*, 2018, 46(D1): D956–D963. doi: [10.1093/nar/gkx1090](https://doi.org/10.1093/nar/gkx1090).
- [16] FRUMAN D A, ROMMEL C. PI3K and cancer: lessons, challenges and opportunities. *Nat Rev Drug Disc*, 2014, 13(2): 140–156. doi: [10.1038/nrd4204](https://doi.org/10.1038/nrd4204).
- [17] BRANA I, PHAM N A, KIM L, *et al*. Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. *Oncotarget*, 2017, 8: 84659–84670. doi: [10.18632/oncotarget.19109](https://doi.org/10.18632/oncotarget.19109).
- [18] TSUBAKI M, TAKEDA T, NOGUCHI M, *et al*. Overactivation of Akt contributes to MEK inhibitor primary and acquired resistance in colorectal cancer cells. *Cancers (Basel)*, 2019, 11(12): 1866. doi: [10.3390/cancers11121866](https://doi.org/10.3390/cancers11121866).
- [19] LIU H, PADDOCK M N, WANG H, *et al*. The INPP4B tumor suppressor modulates EGFR trafficking and promotes triple-negative breast cancer. *Cancer Discov*, 2020, 10(8): 1226–1239. doi: [10.1158/2159-8290.CD-19-1262](https://doi.org/10.1158/2159-8290.CD-19-1262).
- [20] FEDELE C G, OOMS L M, HO M, *et al*. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. *Proc Natl Acad Sci U S A*, 2010, 107(51): 22231–22236. doi: [10.1073/pnas.1015245107](https://doi.org/10.1073/pnas.1015245107).
- [21] LI CHEW C, LUNARDI A, GULLUNI F, *et al*. *In Vivo* role of INPP4B in tumor and metastasis suppression through regulation of PI3K-AKT signaling at endosomes. *Cancer Discov*, 2015, 5(7): 740–751. doi: [10.1158/2159-8290.CD-14-1347](https://doi.org/10.1158/2159-8290.CD-14-1347).
- [22] HODGSON M C, SHAO L J, FROLOV A, *et al*. Decreased expression and androgen regulation of the tumor suppressor gene *INPP4B* in prostate cancer. *Cancer Res*, 2011, 71(2): 572–582. doi: [10.1158/0008-5472.CAN-10-2314](https://doi.org/10.1158/0008-5472.CAN-10-2314).
- [23] HODGSON M C, DERYUGINA E I, SUAREZ E, *et al*. INPP4B suppresses prostate cancer cell invasion. *Cell Commun Sign*, 2014, 12: 61. doi: [10.1186/s12964-014-0061-y](https://doi.org/10.1186/s12964-014-0061-y).
- [24] CHAURASIYA S, WU W, STROM A M, *et al*. Estrogen receptor β regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3. *Proc Natl Acad Sci U S A*, 2020, 117(42): 26347–26355. doi: [10.1073/pnas.2007160117](https://doi.org/10.1073/pnas.2007160117).
- [25] ZHANG F, LI J, ZHU J, *et al*. IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells. *Biol Res*, 2019, 52(1): 11. doi: [10.1186/s40659-019-0218-7](https://doi.org/10.1186/s40659-019-0218-7).
- [26] DZNELADZE I, HE R, WOOLLEY J F, *et al*. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. *Leukemia*, 2015, 29(7): 1485–1495. doi: [10.1038/leu.2015.51](https://doi.org/10.1038/leu.2015.51).
- [27] RUAN X H, LIU X M, YANG Z X, *et al*. INPP4B promotes colorectal cancer cell proliferation by activating mTORC1 signaling and cap-dependent translation. *Oncotargets Ther*, 2019, 12: 3109–3117. doi: [10.2147/OTT.S186365](https://doi.org/10.2147/OTT.S186365).
- [28] YANG L, DING C, TANG W, *et al*. INPP4B exerts a dual function in the stemness of colorectal cancer stem-like cells through regulating Sox2 and Nanog expression. *Carcinogenesis*, 2020, 41(1): 78–90. doi: [10.1093/carcin/bgz110](https://doi.org/10.1093/carcin/bgz110).
- [29] TREGUNNA R. Serum MMP7 levels could guide metastatic therapy for prostate cancer. *Nat Rev Urol*, 2020, 17(12): 658. doi: [10.1038/s41585-020-00396-3](https://doi.org/10.1038/s41585-020-00396-3).
- [30] HAN B, ZHOU B, QU Y, *et al*. FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer. *Oncogene*, 2018, 37(10):1399-1408. doi: [10.1038/s41388-017-0021-2](https://doi.org/10.1038/s41388-017-0021-2).
- [31] GAO Y, NAN X, SHI X, *et al*. SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF- κ B pathway activation. *BMC Cancer*, 2019, 19(1): 685. doi: [10.1186/s12885-019-5904-x](https://doi.org/10.1186/s12885-019-5904-x).
- [32] AZIZAN S, CHENG K J, MEJIA MOHAMED E H, *et al*. Insights into the molecular mechanisms and signalling pathways of epithelial to mesenchymal transition (EMT) in colorectal cancer: a systematic review and bioinformatic analysis of gene expression. *Gene*, 2024, 896: 148057. doi: [10.1016/j.gene.2023.148057](https://doi.org/10.1016/j.gene.2023.148057).
- [33] CHEN L, KE X. MMP7 as a potential biomarker of colon cancer and its prognostic value by bioinformatics analysis. *Medicine (Baltimore)*, 2021, 100(9): e24953. doi: [10.1097/MD.00000000000024953](https://doi.org/10.1097/MD.00000000000024953).
- [34] 陈焕新, 鲁瑞林. MMP-7在直肠癌中的表达及与神经浸润的关系. *华西医学*, 2008, (3): 487–489. doi: [10.3969/j.issn.1002-0179.2008.03.033](https://doi.org/10.3969/j.issn.1002-0179.2008.03.033).
- CHEN H X, LU R L. Expression of MMP7 in rectal adenocarcinoma and its relationship with neural invasion. *West China Med J*, 2008, (3): 487–489. doi: [10.3969/j.issn.1002-0179.2008.03.033](https://doi.org/10.3969/j.issn.1002-0179.2008.03.033).
- [35] BARABÁS L, HRITZ I, ISTVÁN G, *et al*. The behavior of MMP-2, MMP-7, MMP-9, and their inhibitors TIMP-1 and TIMP-2 in adenoma-colorectal cancer sequence. *Dig Dis*, 2021, 39(3): 217–224. doi: [10.1159/000511765](https://doi.org/10.1159/000511765).
- [36] QASIM B J, ALI H H, HUSSEIN A G. Immunohistochemical expression of matrix metalloproteinase-7 in human colorectal adenomas using specified automated cellular image analysis system: a clinicopathological study. *Saudi J Gastroenterol*, 2013, 19(1): 23–27. doi: [10.4103/1319-3767.105916](https://doi.org/10.4103/1319-3767.105916).
- [37] HU Q, LAN J, LIANG W, *et al*. MMP7 damages the integrity of the renal tubule epithelium by activating MMP2/9 during ischemia-reperfusion injury. *J Mol Histol*, 2020, 51(6): 685–700. doi: [10.1007/s10735-020-09914-4](https://doi.org/10.1007/s10735-020-09914-4).
- [38] DOZIER S, ESCOBAR G P, LINDSEY M L. Matrix metalloproteinase (MMP)-7 activates MMP-8 but not MMP-13. *Med Chem*, 2006, 2(5):

- 523–526. doi: [10.2174/157340606778250261](https://doi.org/10.2174/157340606778250261).
- [39] BUFU T, DI X, YILIN Z, *et al.* Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway. *Anticancer Drugs*, 2018, 29(6): 530–538. doi: [10.1097/CAD.0000000000000621](https://doi.org/10.1097/CAD.0000000000000621).
- [40] XU C L, WANG J Z, XIA X P, *et al.* Rab11-FIP2 promotes colorectal cancer migration and invasion by regulating PI3K/AKT/MMP7 signaling pathway. *Biochem Bioph Res Co*, 2016, 470(2): 397–404. doi: [10.1016/j.bbrc.2016.01.031](https://doi.org/10.1016/j.bbrc.2016.01.031).
- [41] LIU G, JIANG C, LI D, *et al.* MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. *Tumour Biol*, 2014, 35(10): 9801–9806. doi: [10.1007/s13277-014-2273-6](https://doi.org/10.1007/s13277-014-2273-6).
- [42] XU Z, LIU D, FAN C, *et al.* DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT/AP-1 pathway. *Mol Carcinog*, 2014, 53(11): 917–925. doi: [10.1002/mc.22059](https://doi.org/10.1002/mc.22059).
- [43] ZHANG J, WANG S, LU L, *et al.* MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi's sarcoma. *Tumour Biol*, 2014, 35(12): 12567–12573. doi: [10.1007/s13277-014-2577-6](https://doi.org/10.1007/s13277-014-2577-6).

(2024 – 02 – 04收稿, 2024 – 08 – 04修回)

编辑 吕 熙



开放获取 本文使用遵循知识共享署名—非商业性使用 4.0国际许可协议 (CC BY-NC 4.0), 详细信息请访问

<https://creativecommons.org/licenses/by/4.0/>。

OPEN ACCESS This article is licensed for use under Creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0). For more information, visit <https://creativecommons.org/licenses/by/4.0/>.

© 2024 《四川大学学报(医学版)》编辑部 版权所有
Editorial Office of *Journal of Sichuan University (Medical Sciences)*